Best Fit Health/Biotechnology Funds ETFs
U.S. News evaluated 29 Health/Biotechnology Funds ETFs and 14 make our Best Fit list. Our list highlights the best passively managed funds for long-term investors. Rankings are assigned based on comparisons with Best Fit funds in this category.
| Best Fit Scorecard | |
|---|---|
| Costs | Excellent |
| Tracking Error | Excellent |
| Bid/Ask Ratio | Typical |
| Holdings Diversity | Good |
Fund Description
The investment seeks to track the performance of a benchmark index. The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index (IMI)/Health Care 25/50, an index made up of stocks of large, mid-size, and small U.S. companies within the health care sector, as classified under the Global Industry Classification Standard (GICS). It attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index. The fund is non-diversified.
Fund Snapshot Updated 05.16.2013
| Previous Close | $87.92 | Expense Ratio | 0.14% |
| YTD Return | 22.7% | Avg. 30-Day Volume | 185,423 |
| 1-Year Return | 36.6% | Market Cap | Loading... |
| Bid | $87.90 | Shares Outstanding | 19,019,000 |
| Ask | $87.93 | Dividends | $1.20 |
| Top 10 Holdings | |
|---|---|
| Johnson & Johnson (JNJ) | 10.90% |
| Pfizer Inc (PFE) | 9.69% |
| Merck & Co Inc New (MRK) | 6.34% |
| Gilead Sciences Inc (GILD) | 3.75% |
| Amgen Inc (AMGN) | 3.62% |
| Abbvie Inc (ABBV) | 3.26% |
| Bristol Myers Squibb Co (BMY) | 3.17% |
| Unitedhealth Group Inc (UNH) | 2.85% |
| Lilly Eli & Co (LLY) | 2.63% |
| Abbott Labs (ABT) | 2.62% |
| % of Total Holdings | 48.80% |
